CD109 and early-onset autosomal dominant Alzheimer disease: Cannabidiol treatment could also reduce the expression of genes involved in the activation of the immune system (CD109,CD151,CD40,CD46,CD59,CD68,CD81,CD82,CD99), while stimulating the expression of genes involved in the inhibition of immune responses (CD47,CD55,CD276) Libro et al. (67) In another study, pretreatment of GMSCs with cannabidiol led to the attenuation of the expression of genes implicated in the etiopathogenesis of Alzheimer’s disease, showing that preconditioned GMSCs have potential for the treatment of early-stage Alzheimer’s disease.